Journal of Infectious Diseases & Therapy
Open Access

Thibault Mesplède

McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Chemin-Côte-Ste-Catherine, Montréal, H3T 1E2, Québec, Canada

Biography

Dr. Thibault Mesplède currently working in McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Chemin-Côte-Ste-Catherine, Montréal, H3T 1E2, Québec, Canada . Dr. Thibault Mesplède has published numerous research papers and articles in reputed journals and has various other achievements in the related studies. Dr.Thibault Mesplèdehas extended valuable service towards the scientific community with extensive research work.

Publications

Is Drug Resistance in First-Line Therapy against All Antiretroviral Agents Inevitable?

Drug resistance has been observed in regard to all anti-retroviral drugs that have been studied until now. The most recent drug to be approved for use in HIV therapy is dolutegravir, an HIV integrase inhibitor, that was approved for therapy by the Food and Drug Administration in the United States in 2013. Dolutegravir is the only HIV drug that has ... Read More»

Mark A Wainberg and Thibault Mesplède

Research Article: J Infect Dis Ther 2015, 3: 208

DOI: 10.4172/2332-0877.1000208

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF